PURPOSE Mantle cell lymphoma (MCL) is a rare aggressive variant of non-Hodgkin lymphoma. Clinical and survival data from India are scarce. MATERIALS AND METHODS We retrospectively analyzed clinicopathologic data of 98 patients with MCL treated at our center in the past 10 years. STATA 13.0 was used for overall survival (OS) and event-free survival (EFS) assessment by Kaplan-Meier analysis. Univariate and multivariate analyses (Cox proportional hazards) were used to identify predictors of survival. P value 60 years, Eastern Cooperative Oncology Group performance status ≥2, advanced stage, and leukocytosis at presentation were associated with poor OS. CONCLUSION Our study was a comprehensive analysis of patients with MCL from India. To our knowledge, this was the first study of its kind demonstrating OS and EFS benefit of RM in MCL from this part of the world.
Datta et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: